HRP20100644T1 - Cijepivo kombinacije peptida protiv alergije na macke - Google Patents
Cijepivo kombinacije peptida protiv alergije na macke Download PDFInfo
- Publication number
- HRP20100644T1 HRP20100644T1 HR20100644T HRP20100644T HRP20100644T1 HR P20100644 T1 HRP20100644 T1 HR P20100644T1 HR 20100644 T HR20100644 T HR 20100644T HR P20100644 T HRP20100644 T HR P20100644T HR P20100644 T1 HRP20100644 T1 HR P20100644T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- polypeptide
- prevention
- treatment
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 23
- 241000282326 Felis catus Species 0.000 title claims abstract 11
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract 10
- 208000026935 allergic disease Diseases 0.000 title claims abstract 10
- 230000007815 allergy Effects 0.000 title claims abstract 10
- 229960005486 vaccine Drugs 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 19
- 239000000203 mixture Substances 0.000 claims abstract 17
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 239000000047 product Substances 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 239000013566 allergen Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000005867 T cell response Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000002009 allergenic effect Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Abstract
Sastav za uporabu u prevenciji ili lijecenju alergije na macke kod pojedinca po toleranciji sastoji se od polipeptida: CPAVKRDVDLFLT (SEQ ID BROJ: 1); EQVAQYKALPVVLENA (SEQ ID broj: 2); KALPVVLENARILKNCV (SEQ ID broj: 3); RILKNCVDAKMTEEDKE (SEQ ID broj: 4); KENALSLLDKIYTSPL (SEQ ID broj: 5); TAMKKIQDCYVENGLI (SEQ ID BROJ: 6); SRVLDGLVMTTISSSK (SEQ ID broj: 7); naznacen time, sto jedan ili vise peptida moze se zamijeniti pomocu varijante ili fragmenta zamijenjenog peptida, pri cemu: (a) varijanta je polipeptid koji se sastoji od dvije ili vise konzervativne supstitucije aminokiselina u usporedbi sa zamijenjenim peptidom, ili (b) varijanta je polipeptid koji ima najmanje 90% identiteta zamijenjenog polipeptida, ili (c) fragment je polipeptid izveden pomocu brisanja jedne ili dvije aminokiseline iz krajeva N ili C terminala, ili jedne amino kiseline iz krajeva N i C terminala iz zamijenjenog peptida, i pri cemu (i), navedena varijanta ili fragment je kadar izazvati imunoloski odgovor kojim je pojedinac neosjetljiv na Fel d 1 protein, i (ii) niti jedne druge peptide prisutne u sastavu. Patent sadrzi jos 13 patentnih zahtjeva.
Claims (14)
1. Sastav za uporabu u prevenciji ili liječenju alergije na mačke kod pojedinca po toleranciji sastoji se od polipeptida:
CPAVKRDVDLFLT (SEQ ID BROJ: 1);
EQVAQYKALPVVLENA (SEQ ID broj: 2);
KALPVVLENARILKNCV (SEQ ID broj: 3);
RILKNCVDAKMTEEDKE (SEQ ID broj: 4);
KENALSLLDKIYTSPL (SEQ ID broj: 5);
TAMKKIQDCYVENGLI (SEQ ID BROJ: 6);
SRVLDGLVMTTISSSK (SEQ ID broj: 7);
naznačen time, što jedan ili više peptida može se zamijeniti pomoću varijante ili fragmenta zamijenjenog peptida, pri čemu:
(a) varijanta je polipeptid koji se sastoji od dvije ili više konzervativne supstitucije aminokiselina u usporedbi sa zamijenjenim peptidom, ili
(b) varijanta je polipeptid koji ima najmanje 90% identiteta zamijenjenog polipeptida, ili
(c) fragment je polipeptid izveden pomoću brisanja jedne ili dvije aminokiseline iz krajeva N ili C terminala, ili jedne amino kiseline iz krajeva N i C terminala iz zamijenjenog peptida,
i pri čemu (i), navedena varijanta ili fragment je kadar izazvati imunološki odgovor kojim je pojedinac neosjetljiv na Fel d 1 protein, i (ii) niti jedne druge peptide prisutne u sastavu.
2. Sastav za uporabu u skladu sa zahtjevom 1, naznačen time, što jedan ili više polipeptida ima jednu ili više modifikacija odabranih iz slijedećeg:
(i) N terminalna acetilacija;
(ii) C terminalna amidacija;
(iii) jedan ili više vodika na strani lanca amina od Arginina i / ili Lizina zamijenjenih sa metilen grupom;
(iv) glikozilacija, i
(v) fosforilaciju.
3. Sastav za uporabu u skladu sa zahtjevima 1 ili 2, naznačen time, što svaki polipeptid ima koncentraciju u rasponu od 0.03 do 200 nmol/ml, 0.3 do 200 nmol/ml ili 10 do 50 nmol/ml.
4. Sastav, naznačen time, što za uporabu u prevenciji ili liječenju alergije na mačke po toleranciji sastoji se od sekvenci polinukleotida koje kada se iskazuju uzrokuju proizvodnju sastava kao što je definirano u bilo kojem zahtjevu 1 do 3.
5. Sastav za uporabu u skladu sa zahtjevom 4, naznačen time, što je svaka sekvenca polinukleotida sposobna iskazati različit polipeptid prisutan u istim ili različitim polinukleotid vektorima.
6. Sastav za uporabu u skladu sa bilo kojim prethodim zahtjevom, naznačen time, što farmaceutski sastav sadrži jedan ili više farmaceutski prihvatljivih nositelja ili otapala.
7. Iskazani vektor, naznačen time, što za uporabu u prevenciji ili liječenju alergije na mačke po toleranciji sastoji se od sedam različitih sekvenci polinukleotida, pri čemu svaka sekvenca polinukleotida kodira jedan od polipeptida kao što je definirano u zahtjevu 1 i gdje je svaka sekvenca polinukleotida operabilno povezana s kontrolnom sekvencom osiguravajući iskaz kodirane sekvence.
8. Proizvod, naznačen time, što za uporabu u prevenciji ili liječenju alergije na mačke po toleranciji sastoji se od polipeptida kao što je definirano u zahtjevu 1, pri čemu svaki različiti polipeptid je simultano, odvojeno ili sekvencijski uporabljen u prevenciji ili liječenju alergije na mačke kod čovjeka.
9. Proizvod, naznačen time, što za uporabu u prevenciji ili liječenju alergije na mačke po toleranciji sastoji se od polinukleotida sposobnih da iskazuju različite polipeptide kao što je definirano u zahtjevu 1, pri čemu svaki različiti polinukleotid je simultano, odvojeno ili sekvencijski uporabljen u prevenciji ili liječenju alergije na mačke kod čovjeka.
10. Farmaceutska formulacija, naznačena time, što za uporabu u prevenciji ili liječenju alergije na mačke po toleranciji sastoji se od sastava u skladu sa bilo kojim zahtjevom 1 do 5; vektora u skladu sa zahtjevom 7; ili proizvoda u skladu sa bilo kojim zahtjevom 8 ili 9; i farmaceutski prihvatljivih nositelja ili otapala.
11. Formulacija za uporabu u skladu sa zahtjevom 10, naznačena time, što je sastav, vektor ili proizvod formuliran za intradermalnu primjenu, oralnu primjenu, nosnu primjenu, potkožnu primjenu, sublingvalnu primjenu ili za primjenu udisanjem ili injektiranjem.
12. Sastav za uporabu kao što je definirano u bilo kojem zahtjevom 1 do 6, ili proizvod kao što je definirano u bilo kojem zahtjevom 8 do 9, naznačeni time, što se dodatno sastoje od daljnjeg alergena polipeptida za uporabu u toleranciji pojedinca do daljnjeg alergen polipeptida, pri čemu daljnji alergen polipeptida je drugačiji od Fel d 1.
13. In vitro metodu utvrđivanja da li pojedinac ima ili je u opasnosti od stanja u kojem je, naznačena time, što je stanje karakterizirano sa alergijskim simptomima kao odgovor na alergene mačke, metoda se sastoji od testiranje da li pojedinac ima T stanice koje reagiraju na sastav kao što je definirano u bilo kojem od zahtjeva 1 do 5, čime bi se utvrdilo da li pojedinac ima ili je u opasnosti od stanja.
14. Metoda u skladu sa zahtjevom 13, naznačena time, što odgovor T-stanice sa navedenim sastavom je mjeren pomoću kontaktiranja sastava sa T stanicama u uzorku izabranom iz predmeta, pod uvjetima koji omogućuju sastav i T stanice na interakciju, te utvrđivanje da li je ili nije bilo koji od T stanica stimuliran; čime bi se utvrdilo da li je ili nije odgovor T-stanice prisutan ili odsutan.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0710529.9A GB0710529D0 (en) | 2007-06-01 | 2007-06-01 | Vaccine |
| PCT/GB2008/001827 WO2008145998A1 (en) | 2007-06-01 | 2008-05-30 | Vaccine peptide combinations against cat allergy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100644T1 true HRP20100644T1 (hr) | 2011-01-31 |
Family
ID=38289716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100644T HRP20100644T1 (hr) | 2007-06-01 | 2010-11-24 | Cijepivo kombinacije peptida protiv alergije na macke |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8551492B2 (hr) |
| EP (3) | EP2079481B2 (hr) |
| JP (2) | JP5366936B2 (hr) |
| CN (2) | CN101808660B (hr) |
| AT (1) | ATE481984T1 (hr) |
| AU (1) | AU2008256524B2 (hr) |
| CA (1) | CA2689260C (hr) |
| CY (1) | CY1110980T1 (hr) |
| DE (1) | DE602008002693D1 (hr) |
| DK (1) | DK2079481T4 (hr) |
| ES (2) | ES2573700T3 (hr) |
| GB (1) | GB0710529D0 (hr) |
| HK (1) | HK1132935A1 (hr) |
| HR (1) | HRP20100644T1 (hr) |
| PL (1) | PL2079481T3 (hr) |
| PT (1) | PT2079481E (hr) |
| SI (1) | SI2079481T1 (hr) |
| WO (2) | WO2008145998A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| CN101820907B (zh) * | 2007-08-15 | 2013-05-01 | 切尔卡西亚有限公司 | 针对过敏原去敏化的肽 |
| SI2153841T2 (sl) | 2008-08-15 | 2016-02-29 | Circassia Limited | Cepivo, ki obsega peptide Amb a 1, za uporabo pri zdravljenju alergije na ambrozijo |
| EP2331124A1 (en) | 2008-08-15 | 2011-06-15 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| NZ594268A (en) | 2009-02-05 | 2013-05-31 | Circassia Ltd | Grass peptides for vaccine |
| GB201002559D0 (en) | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| JO3820B1 (ar) * | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| GB201208293D0 (en) | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| WO2014066939A1 (en) | 2012-10-30 | 2014-05-08 | Monash University | Novel immunotherapeutic molecules and uses thereof |
| EP3564671B1 (en) | 2013-08-23 | 2021-09-29 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| RU2689552C2 (ru) | 2013-09-25 | 2019-05-28 | Аравакс Пти Лтд | Новая иммунотерапевтическая композиция и ее применения |
| GB2523399B (en) * | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| GB2559499A (en) * | 2014-02-25 | 2018-08-08 | Orban Tihamer | Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity |
| US10898568B2 (en) * | 2015-09-30 | 2021-01-26 | Boehringer Ingelheim Vetmedica Gmbh | Modular antigen transportation molecules and uses thereof in animals |
| WO2017139558A1 (en) * | 2016-02-12 | 2017-08-17 | Virtici, Llc | Tolerance therapeutic for treating polypeptide induced immune activation |
| WO2018118713A1 (en) | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| EP4297793A1 (en) * | 2021-02-23 | 2024-01-03 | Spécialités Pet Food | Novel canine odorant binding proteins |
| CN117627400B (zh) * | 2024-01-26 | 2024-04-12 | 辽宁美耐金属建筑系统有限公司 | 一种金属屋面屋脊防坠落系统及防坠方法 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0044532B1 (en) | 1980-07-18 | 1986-04-23 | E.I. Du Pont De Nemours And Company | Monothioglycerol as thiol-protector in lyophilized materials |
| US4442212A (en) * | 1980-11-10 | 1984-04-10 | E. I. Du Pont De Nemours & Company | Monothioglycerol as thiol-protector in lyophilized materials |
| US4855407A (en) | 1985-04-11 | 1989-08-08 | Alpha-1 Biomedicals, Inc. | Solid phase process for synthesizing peptides |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| DK0500785T3 (da) | 1989-11-03 | 2002-08-19 | Immulogic Pharma Corp | Humant T-celleaktivitet felint protein (TRFP) isoleret fra husstøv samt anvendelser heraf |
| US5547669A (en) * | 1989-11-03 | 1996-08-20 | Immulogic Pharma Corp | Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I |
| US6019972A (en) * | 1989-11-03 | 2000-02-01 | Immulogic Pharmaceutical Corporation | Peptides of human T cell reactive feline protein (TRFP) |
| US5593698A (en) | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| US6982326B1 (en) * | 1991-07-12 | 2006-01-03 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from Japanese cedar pollen |
| US6555116B1 (en) | 1991-10-12 | 2003-04-29 | Regents Of The University Of California | Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin |
| DE69233772D1 (de) | 1991-10-16 | 2009-11-12 | Merck Patent Gmbh | T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe) |
| WO1994024281A1 (en) | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| EP0636180A1 (en) | 1992-04-09 | 1995-02-01 | Immulogic Pharmaceutical Corporation | T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA) |
| US5480972A (en) | 1992-10-30 | 1996-01-02 | The University Of Melbourne | Allergenic proteins from Johnson grass pollen |
| CA2152818A1 (en) | 1992-12-31 | 1994-07-21 | Jay P. Morgenstern | Allergenic proteins and peptides from dog dander and uses therefor |
| US5697103A (en) | 1993-01-11 | 1997-12-16 | Personal Expression I, Inc. | Therapeutic glove |
| EP0688338A1 (en) | 1993-03-12 | 1995-12-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of ryegrass pollen allergen |
| WO1994027634A1 (en) | 1993-06-02 | 1994-12-08 | Institute For Child Health Research | Cryptic peptides for use in inducing immunologic tolerance |
| JPH09504167A (ja) | 1993-08-13 | 1997-04-28 | イミュロジック ファーマスーティカル コーポレイション | ドクムギ花粉アレルゲンのｔ細胞エピトープ |
| JPH07215996A (ja) | 1994-01-31 | 1995-08-15 | Torii Yakuhin Kk | ダニアレルゲンのｂ細胞エピトープ |
| US5820862A (en) * | 1994-04-14 | 1998-10-13 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| KR100379161B1 (ko) | 1994-04-14 | 2003-06-11 | 이뮤로직 파마시티컬 코포레이션 | 집먼지진드기에의한알레르기를치료하기위한의학적펩티드조성물 |
| JPH10505356A (ja) | 1994-09-02 | 1998-05-26 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド |
| IL115744A (en) | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
| DE19508192A1 (de) * | 1995-03-09 | 1996-09-12 | Behringwerke Ag | Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung |
| US6737406B1 (en) | 1996-03-21 | 2004-05-18 | Circassia, Ltd. | Cryptic peptides and method for their identification |
| US6238888B1 (en) | 1997-12-22 | 2001-05-29 | Human Genone Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| WO1999034826A1 (en) * | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
| HU229377B1 (hu) | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
| WO2002017956A2 (en) * | 2000-08-31 | 2002-03-07 | Chiron Corporation | Stabilized fgf formulations containing reducing agents |
| US7786257B2 (en) * | 2000-12-18 | 2010-08-31 | University Of Kansas | Signal-1/signal-2 bifunctional peptide inhibitors |
| FR2820425B1 (fr) | 2001-02-08 | 2004-01-02 | Commissariat Energie Atomique | Melange de peptides issus d'une proteine nef et leurs applications |
| AU2002305138A1 (en) | 2001-04-09 | 2002-10-21 | Mayo Foundation For Medical Education And Research | Methods and materials for cancer treatment |
| DE60237841D1 (de) | 2001-11-13 | 2010-11-11 | Genentech Inc | Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung |
| EP1453539B1 (en) | 2001-12-05 | 2008-11-19 | Circassia Limited | Immunotherapeutic methods and systems |
| AUPS148202A0 (en) | 2002-04-02 | 2002-05-09 | Monash University | Immunotherapeutic and immunoprophylactic reagents |
| CA2485217C (en) | 2002-05-06 | 2012-05-01 | Thomas Jefferson University | Insulin-associated peptides with effects on cerebral health |
| US20040071718A1 (en) * | 2002-09-18 | 2004-04-15 | Jaw-Ji Tsai | Local nasal immunotherapy for allergen-induced airway inflammation |
| US8198401B2 (en) | 2003-03-07 | 2012-06-12 | London Health Sciences Centre Research Inc. | Peptides associated with HLA-DR MHC class II molecule and involved in rheumatoid arthritis |
| US7923209B2 (en) * | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
| WO2005000891A2 (en) | 2003-06-26 | 2005-01-06 | Merck Patent Gmbh | Thrombopoietin proteins with improved properties |
| GB0315754D0 (en) | 2003-07-04 | 2003-08-13 | Univ Aberdeen | Pharmaceutical compositions |
| EP1685160A1 (en) | 2003-11-10 | 2006-08-02 | Arriva-Prometic Inc. | Dry recombinant human alpha 1-antitrypsin formulation |
| ATE357928T1 (de) | 2003-12-31 | 2007-04-15 | Orthologic Corp | Pharmazeutische zusammensetzung für thrombinpeptidderivaten |
| US20060029551A1 (en) | 2004-08-05 | 2006-02-09 | Kui Liu | Stable particle formulations of erythropoietin receptor agonists |
| WO2006075253A2 (en) | 2005-01-11 | 2006-07-20 | Commissariat A L'energie Atomique | Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides. |
| EP1843779A2 (en) | 2005-02-01 | 2007-10-17 | Attenuon, LLC | Compositions containing the anti-angiogenic phscn-peptide |
| FR2881746B1 (fr) | 2005-02-07 | 2007-04-13 | Centre Nat Rech Scient | Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications |
| WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| JP2009516718A (ja) * | 2005-11-23 | 2009-04-23 | ウニベルジテート チューリッヒ | 経皮アレルゲン投与によるアレルギー治療 |
| CN1840708A (zh) * | 2006-01-23 | 2006-10-04 | 南开大学 | 用于治疗免疫耐受相关疾病的基因的筛选和鉴定方法 |
| GB0609121D0 (en) | 2006-05-09 | 2006-06-21 | Univ Birmingham | Peptide Therapy |
| GB0701048D0 (en) | 2007-01-18 | 2007-02-28 | Univ Aberdeen | A composition |
| EP1958645A1 (en) | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
| US8148105B2 (en) | 2007-03-16 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Scaleable manufacturing process for cysteine endoprotease B, isoform 2 |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| CN101820907B (zh) | 2007-08-15 | 2013-05-01 | 切尔卡西亚有限公司 | 针对过敏原去敏化的肽 |
-
2007
- 2007-06-01 GB GBGB0710529.9A patent/GB0710529D0/en not_active Ceased
-
2008
- 2008-05-30 CN CN200880101107.8A patent/CN101808660B/zh active Active
- 2008-05-30 WO PCT/GB2008/001827 patent/WO2008145998A1/en active Application Filing
- 2008-05-30 EP EP08762207.2A patent/EP2079481B2/en not_active Not-in-force
- 2008-05-30 JP JP2010509893A patent/JP5366936B2/ja active Active
- 2008-05-30 EP EP11182398.5A patent/EP2428222B1/en active Active
- 2008-05-30 WO PCT/GB2008/001833 patent/WO2008146003A1/en active Application Filing
- 2008-05-30 PL PL08762207T patent/PL2079481T3/pl unknown
- 2008-05-30 ES ES11182398.5T patent/ES2573700T3/es active Active
- 2008-05-30 CA CA2689260A patent/CA2689260C/en active Active
- 2008-05-30 PT PT08762207T patent/PT2079481E/pt unknown
- 2008-05-30 EP EP10006684A patent/EP2380591A3/en not_active Withdrawn
- 2008-05-30 SI SI200830096T patent/SI2079481T1/sl unknown
- 2008-05-30 ES ES08762207.2T patent/ES2353360T5/es active Active
- 2008-05-30 AU AU2008256524A patent/AU2008256524B2/en not_active Ceased
- 2008-05-30 AT AT08762207T patent/ATE481984T1/de active
- 2008-05-30 CN CN201410081704.6A patent/CN104027801A/zh active Pending
- 2008-05-30 US US12/602,313 patent/US8551492B2/en active Active
- 2008-05-30 DE DE602008002693T patent/DE602008002693D1/de active Active
- 2008-05-30 DK DK08762207.2T patent/DK2079481T4/en active
-
2009
- 2009-12-30 HK HK09112345.8A patent/HK1132935A1/xx not_active IP Right Cessation
-
2010
- 2010-11-24 HR HR20100644T patent/HRP20100644T1/hr unknown
- 2010-12-07 CY CY20101101126T patent/CY1110980T1/el unknown
-
2013
- 2013-07-19 JP JP2013150710A patent/JP5857002B2/ja not_active Expired - Fee Related
- 2013-08-22 US US13/973,117 patent/US9168295B2/en active Active
-
2015
- 2015-09-11 US US14/851,842 patent/US20160120965A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100644T1 (hr) | Cijepivo kombinacije peptida protiv alergije na macke | |
| HRP20100662T1 (hr) | Peptidi za desenzibilizaciju protiv alergena | |
| JP2010536333A5 (hr) | ||
| HRP20120206T4 (hr) | Cjepivo koje sadrži amb a 1 peptide za uporabu u lijeäśenju alergije na ambroziju | |
| HRP20161807T1 (hr) | Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže | |
| DK2707014T3 (en) | Dimeric high affinity inhibitors of PSD-95 and their use in the treatment of ischemic brain injury and pain | |
| Van Dijk et al. | Avian cathelicidins: paradigms for the development of anti-infectives | |
| MX348464B (es) | Agente inductor de inmunidad. | |
| ATE538129T1 (de) | Nicht natürliches proteinöses gerüst aus drei nicht kovalent assoziierten peptiden | |
| HRP20160481T1 (hr) | Peptidi za cjepiva protiv alergije na brezu | |
| Chen et al. | Identification and characterization of three novel antimicrobial peptides from Acipenser dabryanus | |
| US20100016549A1 (en) | Peyer's patch and/or m-cell targeting ligands | |
| WO2010111617A4 (en) | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use | |
| Mull et al. | Cyclic peptides that govern signal transduction pathways: From prokaryotes to multi-cellular organisms | |
| HK1129128A1 (en) | Recombinant human interferon-like proteins | |
| TW200716166A (en) | Lawsonia intracellularis immunological proteins | |
| RU2014140231A (ru) | Антимикробные пептиды | |
| KR20110031970A (ko) | 포유류 베타 방어소를 사용한 류마티스성 관절염의 치료 | |
| CA2776883A1 (en) | Antimicrobial and antibiofilm activity of cathelicidins | |
| KR20160019469A (ko) | 코노톡신 펩티드, 제약 조성물 및 그의 용도 | |
| ES2710785T3 (es) | Péptidos antimicrobianos basados en CMAP27 | |
| JP2013535965A5 (hr) | ||
| Zhu et al. | Antimicrobial peptide hepcidin contributes to restoration of the intestinal flora after Aeromonas hydrophila infection in Acrossocheilus fasciatus | |
| CA3021231A1 (en) | Pegylated bioactive peptides and uses thereof | |
| CN103874502B (zh) | 用于控制病原体的氨基酸序列 |